AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03422055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Fucoidan SPECT
Description: Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
Study NCT02402881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered education bundle
Description: A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
Study NCT03874104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extensively Hydrolysed Formula containing Pre- & Probiotics
Description: Extensively Hydrolysed Formula containing Pre- and Probiotics
Study NCT05180604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience learning programs of eHealth care
Description: The experience learning programs of eHealth care was included six sections of activities. Six activities were conducted based on eHealth literacy framework and experience learning theory to improve patients' abilities to engage in eHealth care service. The outcome indicators were eHealth literacy, patient health engagement, the acceptance of eHealth care, eHealth usage status, and their learning experience
Study NCT00507130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 3 mg/kg
Description: MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
Study NCT01105468 — intervention group
Intervention type: DEVICE
Intervention: Breath Collecting Unit
Description: Collect two breath gas samples per patient on one day before surgery
Study NCT01105468 — intervention group
Intervention type: DEVICE
Intervention: Breath Collecting Unit
Description: Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
Study NCT03288727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interviews with a psychologist
Description: an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported.
Study NCT05925829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVF and aaPRP
Description: Stromal vascular fraction and autologous activated platelet-rich plasma
Study NCT04587973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Dexmedetomidine
Description: Ropivacaine plus dexmedetomidine group
Study NCT04587973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Ropivacaine
Description: Plain ropivacaine group
Study NCT04587973 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group Control
Description: Control group
Study NCT04425694 — intervention group
Intervention type: DEVICE
Intervention: e-EWS system
Description: The e-EWS system is connected to a physiological monitor, which takes various physiological measurements. The system has an auto-charting module, which automatically captures patients' physiological measurements in an electronic chart (e-chart) and calculates their EWS. All the information in the auto-charting module is then wirelessly transferred to a central display in the ward's nurses station. The central display shows patients' status in terms of EWS and issues alerts when any EWS has exceeded a set threshold. The e-EWS system is not only capable of auto-charting but also provides an alert mechanism to help nurses detect early deterioration.
Study NCT02031107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cTBS
Study NCT00507130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
Study NCT02553759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actions observed
Description: Patients observed movements without realize them. After this actions, movements will be imagined by patients
Study NCT02553759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Actions observed
Description: Patients observed movements without realize them. After this actions, movements will be imagined by patients
Study NCT02351271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femto LDV Z8
Description: Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
Study NCT02351271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual capsulorhexis&lens fragmentation
Description: Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
Study NCT00149812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Functioning Intervention
Study NCT01650701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: • Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Study NCT01650701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: • Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
Study NCT01650701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab - CHOP
Description: six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
Study NCT01650701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab - CVP
Description: eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
Study NCT01650701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab - Bendamustine
Description: six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Study NCT01158092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with SInergy™ System
Description: Lateral branch denervation using the SInergy™ System
Study NCT01158092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: Treatment with physical therapy, chiropractic care, and medication
Study NCT00005065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00005065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01462812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Sumatriptan 20mg
Study NCT01462812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02031107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cathodal tDCS
Study NCT02031107 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Study NCT02923934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
Study NCT02923934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
Study NCT01391559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arformoterol
Description: 15 mcg administered via nebulizer
Study NCT01391559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol
Description: 50 mcg delivered vis Diskus
Study NCT00005065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: Given IV
Study NCT00005065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo complete surgical resection
Study NCT04278638 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IORT
Description: IORT in surgery of laryngocarcinoma
Study NCT04278638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: total laryngectomy or hemilaryngectomy
Study NCT04278638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: total laryngectomy or hemilaryngectomy
Study NCT04278638 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External radiotherapy
Description: External radiotherapy
Study NCT04278638 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External radiotherapy
Description: External radiotherapy
Study NCT02122250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive web-based materials
Description: Interactive web-based materials for self-management of diabetes
Study NCT02122250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static web-based materials
Description: Static web-based materials
Study NCT03878628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived mesenchymal stem cells
Description: CSCC_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
Study NCT01154855 — intervention group
Intervention type: PROCEDURE
Intervention: Prophylaxis ; Gross debridement for diseased patients
Description: 1 per patient at 2nd visit lasting approximately 1 hour.
Study NCT00960778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)
Description: Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
Study NCT00960778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: denicotinized cigarettes (Quest 3 cigarettes)
Description: Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
Study NCT02628652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GOS
Study NCT02628652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLOS
Study NCT02628652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FOS
Study NCT00005065 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00834925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose diltiazem
Description: Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
Study NCT01994278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peri Clean
Study NCT00815776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clayton Intra-aural Device (CID)
Description: The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID).
Study NCT00815776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mouth Splint
Description: Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
Study NCT00815776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group
Description: Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
Study NCT00176878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10\^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10\^9/kg.
Study NCT00176878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Description: fludarabine 175 mg/m\^2 (total) on Days -6 through -3.
Study NCT00176878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: Dose 500 cGy radiation therapy to specific areas of the body
Study NCT00176878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
Study NCT00176878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
Study NCT03327363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback using ICT based monitoring system
Description: In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
Study NCT03327363 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Feedback using ICT based monitoring system
Description: In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
Study NCT04259034 — intervention group
Intervention type: OTHER
Intervention: diagnosis of periodontitis in oral lichen planus patients
Description: diagnosis of periodontitis in oral lichen planus patients
Study NCT04259034 — intervention group
Intervention type: OTHER
Intervention: diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
Description: diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
Study NCT01789710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
Study NCT01789710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
Study NCT01789710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
Study NCT02785666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grazoprevir/elbasvir, ribavirin
Description: To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
Study NCT02785666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention
Description: To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
Study NCT02236650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Stepping Stones Triple P (PC-SS Triple P)
Description: PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
Study NCT02236650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual for 4 weeks
Study NCT01964287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMBRAX
Study NCT01964287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Study NCT02200068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SANOIA Website
Study NCT00809510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 20 mg ABT-089 taken once-daily for 6 months
Study NCT02353403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar
Description: A 210g chocolate dairy dessert made with 35g of dextrose.
Study NCT02353403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOS
Description: A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
Study NCT00481988 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
Study NCT00481988 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
Study NCT00481988 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
Study NCT00481988 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iomed phoresor transcranial direct current stimulation
Description: for the sham group the current is turned off after 10 seconds
Study NCT02264652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Transcranial Direct Stimulation
Description: Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
Study NCT03216395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-scope Clips
Description: Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.
Study NCT03216395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemo-clipping
Description: Hemo-clipping \<=20 clips
Study NCT03216395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thermo-coagulation
Description: contact thermo-coagulation \< = 8 pulses
Study NCT03216395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: epinephrine injection (diluted 1:1000) beneath peptic ulcer \<20 mls
Study NCT03228992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
Study NCT03228992 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 4 doses of placebo over a 24 hour period.
Study NCT03216668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TONKA
Description: Administered orally twice a day, 2 tablets each time, for 6 weeks.
Study NCT03216668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEGALON
Description: Administered orally three times a day, two tablets each time, for 6 weeks